FDG uptake in giant cell tumor of the tendon sheath in a patient restaged for gastrointestinal stroma tumor (GIST)

Clinical Nuclear Medicine

Volumn 34, Issue 3, 2009, Pages 193-196

  Wissmeyer, Michael ^a,e   Kohl, Sandro ^b   Juengling, Freimut D ^c,e   Stauffer, Edouard ^b,d   Siebenrock, Klaus A ^b   Krause, Thomas M ^e  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c St Claraspital AG   (Switzerland)

^d Institute of Pathology   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

FDG PET; GCTTS; Giant cell tumor of the tendon sheath; GIST

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; GASTROINTESTINAL STROMAL TUMOR; GIANT CELL TUMOR; HIP; HISTOPATHOLOGY; HUMAN; MALE; PERITONEUM TUMOR; POSITRON EMISSION TOMOGRAPHY; TENDON SHEATH; CANCER STAGING; MEMBRANE; METABOLISM; METASTASIS; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; TENDON;

AGED; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; GIANT CELL TUMORS; HUMANS; MALE; MEMBRANES; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; TENDONS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 66849087291     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31819672e2     Document Type: Article

References (15)

1. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-58.
2. Hughes B, Yip D, Goldstein D, et al. Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report. BMC Cancer. 2004;4:74.
3. Gayed I, Vu T, Iyer R, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17-21.
4. Goerres GW, Stupp R, Barghouth G, et al. The value ofPET, CT, and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging. 2005;32: 153-162.
5. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308-314.
6. Even-Sapir E, Lerman H, Gutman M, et al. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur JNuclMed Mol Imaging. 2006;33:541-552.
7. Vock J, Juengling FD, Krause T, et al. Muscular FDG uptake after chewing chewing gum in a patient with Hodgkin disease. Clin Nucl Med. 2007;32:124-127.
8. Bhargava P, Zhuang H, Kumar R, et al. Iatrogenic artifacts on whole-body F-18 FDG PET imaging. Clin Nucl Med. 2004;29:429-439.
9. Bui-Mansfield LT, Youngberg RA, Coughlin W, et al. MRI of giant cell tumor of the tendon sheath in the cervical spine. J Comput Assist Tomogr. 1996;20:113-115.
10. Messoudi A, Fnini S, Labsaili N, etal. Giantcell tumors ofthe tendonsheath of the hand: 32 cases. [in French]. Chir Main. 2007;26:165-169.
11. MonaghanH, Salter DM, Al-Nafussi A. Giantcell tumouroftendonsheath (localised nodular tenosynovitis): clinicopathological features of 71 cases. J Clin Pathol. 2001;54:404-407.
12. Walsh EF, Mechrefe A, Akelman E, et al. Giant cell tumor of tendon sheath. AmJOrthop. 2005;34:116-121.
13. Mackie GC. Pigmented villonodular synovitis and giant cell tumor of the tendon sheath: scintigraphic findings in 10 cases. Clin Nucl Med. 2003;28: 881-885.
14. Aoki J, Watanabe H, Shinozaki T, et al. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses. Skeletal Radiol. 2003;32:133-138.
15. Anazawa U, Hanaoka H, Shiraishi T, et al. Similarities between giant cell tumorofbone, giantcell tumoroftendonsheath, andpigmentedvillonodular synovitis concerning ultrastructural cytochemical features of multinucleated giant cells and mononuclear stromal cells. Ultrastruct Pathol. 2006;30:151- 158.